Gland Pharma’s shares fell more than 3% following the announcement of its first-quarter results for the fiscal year 2024-25 (Q1FY25). As of 10:05 AM, the shares were trading 3.51% lower at ₹2,032.95.
Financial Highlights
- Net Profit: Decreased by 25.9% year-on-year (YoY) to ₹143.8 crore, down from ₹194 crore in Q1FY24.
- Revenue from Operations: Increased by 16% to ₹1,401.7 crore, compared to ₹1,208.7 crore in the same quarter last year.
- EBITDA: Dropped by 10% to ₹264.4 crore, down from ₹293.9 crore in the previous year.
- EBITDA Margin: Reduced to 19% from 24.3% in Q1FY24.
| Metric | Q1 FY25 | Q1 FY24 | Change (%) |
|---|---|---|---|
| Net Profit | ₹143.8 crore | ₹194 crore | -25.9% |
| Revenue | ₹1,401.7 crore | ₹1,208.7 crore | 16% |
| EBITDA | ₹264.4 crore | ₹293.9 crore | -10% |
| EBITDA Margin | 19% | 24.3% | – |
Gland Pharma’s weak performance in net profit and EBITDA despite a rise in revenue has led to a significant decline in its share price.